Hazard ratios for clinical characteristics according to tumor subtype, breast cancer–specific mortality, adjusted for race, age at diagnosis, and date of diagnosis
| All | Basal-like | Luminal A | Luminal B | HER2+/ER− | Unclassified | |
|---|---|---|---|---|---|---|
| (n = 1,149) | (n = 205) | (n = 625) | (n = 112) | (n = 73) | (n = 134) | |
| Stage | ||||||
| Stage I | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Stage II or III | 2.9 (2.0–4.1) | 3.6 (1.4–9.1) | 3.0 (1.8–5.0) | 2.6 (0.9–7.6) | 3.6 (0.8–15.8) | 1.3 (0.6–2.9) |
| Stage IV | 12.7 (7.4–21.7) | 6.4 (1.5–27.0) | 18.9 (7.8–46.0) | 11.0 (1.8–68.6) | 14.0 (2.5–77.5) | 13.1 (3.8–45.8) |
| Tumor size | ||||||
| ≤2 cm | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| >2–5 cm | 2.2 (1.7–3.1) | 1.5 (0.8–2.9) | 2.5 (1.6–4.0) | 2.0 (0.8–4.9) | 2.7 (0.8–9.6) | 1.8 (0.8–4.1) |
| >5 cm | 3.9 (2.7–5.9) | 3.2 (1.5–7.1) | 5.3 (2.9–9.8) | 3.3 (1.0–11.5) | 9.4 (2.2–40.1) | 1.0 (0.3–3.7) |
| Number of lymph nodes positive for malignancy | ||||||
| None | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| 1—2 | 2.0 (1.4–3.8) | 2.7 (1.4–5.4) | 2.2 (1.2–3.9) | 1.6 (0.5–5.6) | 2.0 (0.5–7.3) | 1.0 (0.3–3.6) |
| 3—5 | 3.7 (2.5–5.4) | 6.4 (2.6–15.5) | 4.9 (2.7–8.7) | 2.4 (0.7–8.3) | 2.5 (0.9–7.3) | 1.8 (0.6–5.7) |
| ≥6 | 5.4 (3.9–7.5) | 7.2 (3.7–14.2) | 7.7 (4.5–13.0) | 5.4 (1.9–14.7) | 4.7 (1.6–14.4) | 1.9 (0.7–4.9) |
| Metastasis | ||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Yes | 5.8 (3.7–9.2) | 2.2 (0.7–7.2) | 8.9 (4.0–19.4) | 5.2 (1.1–25.3) | 4.5 (1.6–12.7) | 11.3 (3.7–34.9) |